{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-003725","form_type":"8-K","ticker":"CYCN","cik":"0001755237","company_name":"Cyclerion Therapeutics, Inc.","filed_at":"2021-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.953672+00:00","generated_at":"2026-06-28T10:53:09.712804+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cyclerion reports Q3 net loss $11.3M, cash $63M; pipeline advances in CIAS, ADv, MELAS","bullets":["Net loss of $11.3M improved from $18.8M in Q3 2020; R&D expenses down to $7.0M.","Cash, cash equivalents, and restricted cash $63M, down from $70M at June 30, 2021.","First patients enrolled in CIAS study (CY6463); patient screening underway in ADv study.","MELAS study enrollment slowed by COVID-19; topline clinical results expected H1 2022.","G&A expenses decreased to $4.6M from $8.0M, driven by lower salaries and financing fees."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-003725","json":"https://secwatch.observer/filing/0000950170-21-003725.json","markdown":"https://secwatch.observer/filing/0000950170-21-003725.md","text":"https://secwatch.observer/filing/0000950170-21-003725.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1755237/000095017021003725/0000950170-21-003725-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1755237/000095017021003725/cycn-20211109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T10:53:09.712804+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}